Neuroprotective Potential of Peroxisome Proliferator Activated Receptor-α Agonist in Cognitive Impairment in Parkinson’s Disease: Behavioral, Biochemical, and PBPK Profile

Figure 4

(a) Quantification of DNA fragmentation observed in TUNEL assay. (b) Tyrosine hydroxylase immunohistochemistry and effect of fenofibrate. ^∗∗∗𝑃<0.001 MPTP versus sham, ^@@@𝑃<0.001 MPTP + vehicle versus sham, ^##𝑃<0.01, ^###𝑃<0.001 MPTP versus feno 10, 30, and 100 mg/kg treated groups, ^††𝑃<0.01, ^†††𝑃<0.001 MPTP + vehicle versus feno 10, 30, and 100 mg/kg group. All readings are expressed as mean ± SEM (𝑛=3) and images were acquired at 40X magnification.

(a)

(b)